RT Journal Article
SR Electronic
T1 Use of old and new oral 5-aminosalicylic acid formulations in inflammatory bowel disease
JF Cleveland Clinic Journal of Medicine
JO Cleve Clin J Med
FD Cleveland Clinic
SP 317
OP 323
VO 62
IS 5
A2 Donald G. Vidt
A1 Aaron Brzezinski
A1 George B. Rankin
A1 Douglas L. Seidner
A1 Bret A. Lashner
YR 1995
UL http://www.ccjm.org/content/62/5/317.abstract
AB SUMMARY Although sulfasalazine, a 5-aminosalicylic acid (5-ASA) agent, is still the anti-inflammatory agent of choice for ulcerative colitis and Crohn's disease, newer formulations, which release drug to specific regions of the colon for maximal efficacy, also can be appropriate first-line agents. This article reviews recent clinical studies of therapy with older and newer 5-ASA formulations.